The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.